Sincerely
Dr Erlinda M. Gordon and Dr Sant P. Chawla
Biographies
Dr Erlinda Maria Gordon, MD
Dr Gordon is Director of Biological and Immunological Therapies at the Cancer Centre of Southern California and Chair of the Aveni Foundation, a non-profit organization based in Santa Monica CA, whose mission is to rapidly develop gene targeted therapies for cancer. Dr Gordon is the FDA Sponsor of a planned Phase 2 multicentre study of DeltaRex-G, a targeted genetic medicine for advanced pancreatic cancer, and a collaborator in a program grant entitled “Cell Cycle Checkpoint Inhibitors for Pancreatic Cancer Gene Therapy”. Dr Gordon is also principal investigator of an on-going Phase 2 study using Trabectedin, Ipilimumab and Nivolumab as first line therapy for soft tissue sarcoma funded by Bristol Myers Squibb and co-investigator of over 20 cancer clinical trials. Dr Gordon completed her residency and post-doctoral fellowship in Paediatric Haematology/Oncology at CWRU University Hospitals of Cleveland. She was a tenured Associate Professor of Paediatrics at the USC Keck School of Medicine for 24 years. Dr Gordon is founder of 3 biotech companies and co-inventor of > 200 patents. She was recipient of the Thomas Award for Excellence in Medical Research in 2016 from the University of Santo Tomas School of Medicine, Philippines, where she received her medical degree.
Conflict of Interest: Dr Gordon is PI of an Investigator Initiated Research study funded by BMS.
Dr Sant P. Chawla, MD, FRACP
Dr Chawla is a Diplomate of the American Board of Internal Medicine/Medical Oncology and Director of the Sarcoma Oncology Centre in Santa Monica, CA. His research has led to his recognition as one of the world’s leading authorities in bone and soft-tissue sarcomas and sarcoma therapy. He has authored more than 100 publications in peer-reviewed medical and scientific journals. He is a frequent speaker/presenter at national and international conferences such as the American Society of Clinical Oncology and Connective Tissue Oncology Society. Dr Chawla maintains strong academic affiliations as Associate Professor of Medicine at the University of Texas/M.D. Anderson Cancer Centre, as clinical faculty of the Medical Centre of UCLA, USC Keck School of Medicine, John Wayne Cancer Institute and Cedar-Sinai Medical Centre. Dr Chawla received his Medical Degree at the All India Institute of Medical Sciences in New Delhi. He then specialized in medical oncology at the Auckland Hospital, New Zealand, following which he completed his post-doctoral fellowship in medical oncology at the M.D. Anderson Cancer Centre, Houston TX.
Posted on
Previous Article
« Sentinel lymph node biopsy shows promise for early oral cancer Next Article
Lurbinectedin shows promise as second-line therapy for SCLC »
« Sentinel lymph node biopsy shows promise for early oral cancer Next Article
Lurbinectedin shows promise as second-line therapy for SCLC »
Table of Contents: ASCO 2019
Featured articles
Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer
Breast Cancer
Endocrine therapy plus ribociclib yields overall survival advantage in HR+/HER2-negative breast cancer
Biomarker analysis predicts response to adjuvant trastuzumab, pertuzumab in HER2+ breast cancer
Melanoma
Nivolumab-mediated adverse events are independent of efficacy in resected advanced melanoma
Kidney Cancer
Classification of metastatic renal cell carcinoma patients in immunotherapy era and positive responses for sarcomatoid tumours
Sarcoma
Olaratumab trial in soft tissue sarcoma fails to meet overall survival endpoint
Gastrointestinal Cancers
FOLFOXIRI plus bevacizumab an option for patients with mCRC and poor prognosis
KEYNOTE-062: Pembrolizumab combination fails to improve survival in gastric/GEJ cancer
Neoadjuvant chemotherapy as a potential treatment option in colon cancer
Laparascopic surgery; less morbidity, same survival benefits as open surgery in colorectal cancer with liver metastases
Maintenance olaparib improved PFS in patients with BRCA+ pancreatic cancer
Hematologic Malignancies
Daratumumab a promising treatment option for transplant-eligible multiple myeloma
Paediatric Oncology
Entrectinib produces rapid and durable responses in children with refractory CNS and solid tumours
Head and Neck Cancer
Ado-trastuzumab emtansine a potential new treatment option for HER2-amplified advanced salivary gland cancer
Sentinel lymph node biopsy shows promise for early oral cancer
Genitourinary Cancer - Prostate Cancer
Enzalutamide offers survival advantage over other NSAAs in mHSPC
Benefits seen with apalutamide plus ADT in metastatic castration-sensitive prostate cancer
Enfortumab vedotin highly active in previously treated advanced urothelial carcinoma
Multiple Myeloma
Anti-CD38 antibody isatuximab improves treatment response, PFS in R/R multiple myeloma
Lung Cancer
Neoadjuvant nivolumab/ipilimumab shows promise in resectable NSCLC
Overcoming the challenges of immunotherapy in non–small cell lung cancer
Repotrectinib shows encouraging safety, efficacy for patients with ROS1+ NSCLC
Pembrolizumab monotherapy leads to 5-year survival in some patients with NSCLC
Novel RET inhibitor BLU-667 offers promise for RET+ advanced NSCLC
Lurbinectedin shows promise as second-line therapy for SCLC
Early results from TAK-788 in NSCLC with EGFR exon 20 insertions
Developmental Therapeutics - Immunotherapy
IL-6 and C-reactive protein as potential biomarkers for checkpoint inhibition
First-in-human study shows IL1RAP-targeting drug safe in solid tumours
Related Articles
August 5, 2022
Novel treatment option for KRAS wildtype pancreatic cancer
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com